Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)COVID-19 환자에서 회복기 혈장 요법의 효능: 무작위 대조 시험(COPLA-II 시험)Clinical Trial Published on 2022-04-062022-09-12 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 1:1 48 hour adverse events allergic reaction Antibody titre Blood blood bank & Clinical improvement clinical outcomes collected conducted convalescent plasma Convalescent plasma therapy COVID-19 COVID-19 patient cytokine level D-dimer Efficacy Hospital admission hospitalisation in both group incidence initial IQR median median time Mortality no difference on mechanical ventilation outcome PaO participant Patient plasma proportion randomised randomised controlled trial reduction in SARS-CoV-2 antibody secondary severe COVID-19 patients study population the patient therapy TNF-α transfused Transfusion medicine Treatment treatment group Trial [DOI] 10.1136/bmjopen-2021-055189 PMC 바로가기 [Article Type] Clinical Trial
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials건강한 성인에서 코로나백 3차 접종의 면역원성 및 안전성, 2회 접종 일정의 면역 지속성: 2건의 단일 센터, 이중 맹검, 무작위, 위약 대조 임상 2상 임상 시험의 중간 결과Clinical Trial Published on 2022-04-012022-09-12 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 1:1 95% CI Abstract Administered Adverse reaction analysed antibody Antibody titre assigned Beijing booster dose China clinical trial clinical trials Cohort cohorts Concentration CoronaVac country Cutoff declined development dose doses double-blind eligible foundation GenBank accession number generate geometric geometric mean titre GMIs GMT GMTs groups healthy immune memory immune persistence immune response immunogenicity Inactivated vaccine increase increase in injection Jiangsu material natural neutralising antibody neutralising antibody titre Older outcome participant per-protocol population phase 2 trial Placebo placebo group placebo-controlled positive Program protocol amendment randomised Randomly recalled receive Registered reported resulting SARS-CoV-2 Science second dose Serious Adverse Event seropositive severity significantly increased technology threshold translation Trial vaccination vaccination against COVID-19 vaccination schedule Vaccine virus strain [DOI] 10.1016/S1473-3099(21)00681-2 PMC 바로가기 [Article Type] Clinical Trial
Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based studyCoronaVac, BNT162b2, ChAdOx1 COVID-19 백신 및 단일 추가 접종 후 SARS-CoV-2 anti-spike 수용체 결합 도메인 IgG 항체 반응의 비교: 전향적, 종단적 인구 기반 연구Article Published on 2022-04-012022-09-12 Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI addition age Anti-spike Anti-spike RBD IgG antibody antibody level Antibody Response Antibody titre antibody titres baseline characteristics blood sample BNT162b2 boost booster booster dose ChAdOx1 ChAdOx1 vaccines collected concentrations CoronaVac COVID-19 pandemic COVID-19 vaccines Cyprus distribution dose evaluated Follow-up General population geometric group health-care help high-risk population highest IgG IgG antibody individual inoculated Laboratory Longitudinal data Male sex of BNT162b2 offered Older Older age participant RBD Reactions Receptor binding domain recruited regimen repeated measure Responder response SARS-CoV-2 second dose significantly significantly increased titre vaccination Vaccination strategies Vaccine was done [DOI] 10.1016/S2666-5247(21)00305-0 PMC 바로가기 [Article Type] Article
Humoral response to SARS-CoV-2 infection among liver transplant recipients간 이식 환자의 SARS-CoV-2 감염에 대한 체액 반응Multicenter Study Published on 2022-04-012022-09-11 Journal: Gut [Category] Coronavirus, COVID19(2023년), SARS, 치료기술, 치료법, [키워드] anti-S antibody antibody Antibody Response Antibody testing Antibody titre assigned B lymphocytes case-control study Cohort cohorts controls COVID-19 COVID-19 symptom COVID-19 symptoms criteria detectable expected functional humoral Humoral response immune immune response Immunosuppression Immunosuppressive agents interfere less liver liver transplant Liver transplantation majority mounted multicentre neutralising ability Neutralising activity no difference nucleocapsid protein Patient Prospective Protein recipient recipients required SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 antigens SARS-COV-2 infection Serologic response significantly lower subject Symptoms Testing the antibody response with COVID-19 [DOI] 10.1136/gutjnl-2021-326609 PMC 바로가기 [Article Type] Multicenter Study
Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds표준화된 정량적 중화 분석을 사용하여 우려되는 SARS-CoV-2 변이체의 중화 계층은 질병 심각도와의 상관관계를 보여줍니다. 보호항체 역치를 해독하기 위해Article Published on 2022-03-072022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 진단, [키워드] (Alpha) (Beta) 20/136 Alpha anti-SARS-CoV-2 anti-SARS-CoV-2 immunoglobulin antibody Antibody titre Asymptomatic B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta Cohort concern convalescent sera correlates of protection (CoP) COVID-19 Critical care Delta did not produce disease disease severity First wave Gamma HCW HCWs healthcare worker Healthcare workers hierarchy Immunoglobulin individual International international standard international units IU/mL K417N Laboratory laboratory findings mild case mild cases National neutralisation neutralise P.1 Pseudotyped virus pursuit reduction in SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sera severe COVID-19 Standard Symptoms the WHO threshold titre titres to define unit utilised variants variants of concern variants of interest VoC VOCs WHO World Health Organisation [DOI] 10.3389/fimmu.2022.773982 PMC 바로가기 [Article Type] Article
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants다양한 SARS-CoV-2 변이체에 대한 삼중 백신 접종자의 기억 B 세포 레퍼토리Article Published on 2022-03-012022-09-11 Journal: Nature [Category] MERS, SARS, 변종, 진단, [키워드] active against antibody Antibody titre B.1.1.529 B.1.351 Beta binding class complex defined determinant dose Effectiveness epitope Epitopes examined FIVE geometric geometric mean greater human monoclonal antibodies Human monoclonal antibody immunization inactivated individual Infection Local memory B cell memory B cells mice monoclonal antibodies mutated neutralization neutralize neutralized Neutralizing Neutralizing antibodies neutralizing antibody neutralizing monoclonal antibody omicron Protective raising Receptor-binding domain recipient recipients regimen sarbecovirus SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variant sera seroconversion rate seroconversion rates Spike protein Structure subset target the receptor-binding domain therapy Treatment Vaccine vaccine doses vaccinee vaccinees variants of concern virus [DOI] 10.1038/s41586-022-04466-x PMC 바로가기 [Article Type] Article
Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) RegistryRandomized Controlled Trial Published on 2022-03-012022-10-04 Journal: European journal of internal medicine [Category] SARS, 임상, [키워드] absence Administered Admission adverse event adverse events age anti-SARS-CoV-2 antibody Antibody titre Arterial hypertension Cancer cardiovascular disease CCP CCP administration CCP therapy chest CT scan chest X-ray Chronic kidney disease Comorbidity condition consolidation contribute convalescent convalescent plasma COVID-19 COVID-19 patient Data analysis death Deceased disease drug early treatment Elderly patient enrolled Factor Follow-up fraction Frequency greater hospital Hospitalization hospitalized patients Inclusion inclusion criteria Inpatient intensive care unit interstitial Italy life-threatening lung involvement mechanical ventilation Mortality Neutralizing neutralizing antibody objective Older age outcome overcome oxygen oxygen saturation Oxygen therapy PaO Patient patients treated patients with COVID-19 plasma Primary outcome Prognosis progression radiological randomized controlled study reduced registry respiratory rate SARS CoV-2 SARS-CoV-2 SARS-COV-2 infection severe COVID-19 shown significantly tachypnea TFS therapeutic titre transfused treated Treatment Veneto Veneto region. were recorded [DOI] 10.1016/j.ejim.2021.12.023 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis다발성 경화증 환자에서 SARS-CoV-2에 대한 비활성화 및 mRNA 백신의 안전성 및 체액 반응률Observational Study Published on 2022-03-012022-09-12 Journal: Multiple sclerosis and related disorders [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] adenoviral vector vaccine Adverse age Analysis anti-SARS-CoV-2 vaccines Antibody titre antibody titres booster collected Complete COVID-19 Effectiveness Europe event Evidence first vaccination help humoral Humoral response inactivated Inactivated vaccine Inactivated virus information local pain mRNA mRNA vaccine Multiple multiple sclerosis no increase North America outcome Oxford-AstraZeneca Patient patient cohort patients performed populations positive predictor Protein receiving Safe Safety SARS-CoV-2 sclerosis selected significantly lower therapy vaccination Vaccine virus was determined were recorded women [DOI] 10.1016/j.msard.2022.103690 PMC 바로가기 [Article Type] Observational Study
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variantsSARS-CoV-2 변이체에 대한 보호 예측 인자로서의 중화 항체 역가Comment Published on 2022-03-012022-09-11 Journal: The Lancet. Microbe [Category] MERS, SARS, 변종, 진단, [키워드] Antibody titre predictor SARS-CoV-2 variant [DOI] 10.1016/S2666-5247(21)00337-2 PMC 바로가기 [Article Type] Comment
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial중국 성인을 대상으로 한 SARS-CoV-2 ARCoV mRNA 백신의 안전성 및 면역원성: 무작위 배정, 이중 맹검, 위약 대조, 1상 시험Clinical Trial Published on 2022-03-012022-09-11 Journal: The Lancet. Microbe [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] abnormal change abnormal changes Academy administration adverse event adverse events Adverse reaction Adverse reactions All participant All participants analyses Analysis Anti-RBD IgG anti-SARS-CoV-2 Antibody titre assigned baseline block Block randomisation caused cellular immune responses China Chinese clinical testing conducted convalescent patient Convalescent patients COVID-19 pandemic development domain dose dose-escalation doses double-blind effective vaccine Effective vaccines eligible participant ELISA ELISPOT ENCODE enrolled enzyme enzyme-linked immunospot expected exploratory Fever first vaccination FIVE foundation grade 3 group groups highest hospital humoral humoral immune responses Humoral response humoral responses IFN-γ IL-2 immune immune response immune responses immunogenicity incidence individual Intramuscular injection investigators Laboratory laboratory analyses Laboratory test Laboratory tests live SARS-CoV-2 lowest majority Medical Science Medical Sciences Mild moderate mRNA vaccine natural neutralisation assays Neutralising Antibodies neutralising antibody observation outcome participant Participants peaked Phase 1 phase 1 trial Placebo placebo group placebo-controlled Primary outcome pseudovirus randomised Randomly RBD RBD IgG RBD-specific IgG receive Registered reported research and development resolved Safe Safety safety analyses safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-specific T-cell response SARS-CoV-2-specific T-cell responses Science screened second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events Seven significantly Specific Specific T-cell response Spike protein Support systemic adverse event T-cell Response T-cell responses the placebo group the SARS-CoV-2 titre titres Tolerability treatment allocation Trial vaccination Vaccine vaccine dose vaccine doses were assessed were given with COVID-19 Zhejiang [DOI] 10.1016/S2666-5247(21)00280-9 PMC 바로가기 [Article Type] Clinical Trial